Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCARDIA XL vs ADALAT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
30-90 mg orally once daily, extended-release tablet.
10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.
Terminal elimination half-life: 6-11 hours; clinical context: steady-state achieved after 2-3 days of once-daily dosing.
Terminal elimination half-life: 2-5 hours (immediate-release); 8-14 hours (extended-release). Context: shorter half-life necessitates multiple daily dosing for immediate-release; extended-release allows once-daily dosing.
Hepatic metabolism primarily via CYP3A4
Hepatic via CYP3A4; extensive first-pass metabolism; metabolites are inactive.
Renal: 70-80% as metabolites, <1% unchanged; Fecal: 15-20% via bile.
Renal: 70-80% as metabolites; Fecal: 15-20% as metabolites; <1% unchanged in urine
92-98% bound primarily to albumin.
92-98% bound to plasma proteins (albumin and alpha-1-acid glycoprotein)
0.78-1.6 L/kg; high Vd indicates extensive tissue distribution.
0.8-1.2 L/kg. Clinical meaning: indicates extensive tissue distribution, consistent with high lipophilicity.
Oral (extended-release): 65-85% due to first-pass metabolism; absolute bioavailability 45-65%.
Oral immediate-release: 45-60% (due to first-pass metabolism); extended-release: 60-85% (due to slower release and reduced first-pass effect).
No specific dose adjustment for GFR; use with caution in renal impairment due to potential accumulation of metabolites.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, use with caution and reduce initial dose by 50%.
Child-Pugh A and B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce by 75%.
Safety and efficacy not established; use not recommended.
0.25-0.5 mg/kg/dose orally every 6-8 hours; maximum 3 mg/kg/day. Extended-release not recommended.
Start at lowest dose (30 mg daily) and titrate slowly; monitor for hypotension and peripheral edema.
Start at 10 mg orally twice daily; titrate slowly due to increased sensitivity and risk of hypotension.
Increased risk of cardiovascular events and mortality in patients with coronary artery disease when using short-acting nifedipine; use with caution.
None
May cause severe hypotension, especially in patients on beta-blockers,Can exacerbate angina or cause myocardial infarction upon initiation or dose increase,Peripheral edema is common and dose-dependent,Avoid grapefruit juice which increases nifedipine levels,Use caution in patients with hepatic impairment
May cause hypotension, especially in patients on beta-blockers or with poor cardiac reserve,Risk of increased angina and/or myocardial infarction upon initiation or dose increase,Peripheral edema,Stevens-Johnson syndrome and toxic epidermal necrolysis (rare),Hepatic impairment,Exacerbation of angina on withdrawal
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin) due to decreased efficacy
Hypersensitivity to nifedipine,Cardiogenic shock,Significant aortic stenosis,Concurrent use with rifampin,Pregnancy (category C)
Avoid grapefruit and grapefruit juice. Grapefruit inhibits CYP3A4, increasing nifedipine plasma concentrations and risk of toxicity. High-fat meals may slightly increase absorption but no specific restriction.
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 and increase nifedipine serum concentrations, leading to enhanced hypotensive effects and risk of toxicity. Grapefruit interaction persists for 24 hours; separate consumption by at least 4 hours if unavoidable, but preferable to avoid entirely. Avoid alcohol which can increase hypotension. High-fat meals may reduce absorption of extended-release formulations; take consistently with or without food.
In animal studies, nifedipine caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies, phalangeal malformations) at doses 30-100 times the maximum recommended human dose. In humans, no adequate controlled studies; however, case reports and observational studies suggest an increased risk of preterm birth and possibly fetal distress after third-trimester use. Use in the first trimester is associated with possible cardiovascular defects. Avoid in pregnancy unless benefit clearly outweighs risk.
First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibition. Category C.
Nifedipine is excreted into breast milk in concentrations similar to maternal plasma (M/P ratio approximately 1.0). In clinical studies, no adverse effects in nursing infants have been reported, but caution is advised, especially in neonates with compromised cardiac function.
Excreted in breast milk; M/P ratio ~0.85. Consider risks versus benefits; monitor infant for hypotension.
No specific dosing adjustments are recommended for nifedipine in pregnancy. However, due to increased volume of distribution and hepatic blood flow in pregnancy, lower trough levels may occur; clinical response and tolerability should guide dosing. Use immediate-release with caution in preterm labor; sustained-release formulations preferred for chronic hypertension.
No standard dose adjustment; monitor clinical response and blood pressure; may require lower doses due to vasodilation effects.
PROCARDIA XL (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid grapefruit juice due to CYP3A4 inhibition increasing nifedipine levels. Do not crush or chew tablets; swallow whole. Monitor for peripheral edema, especially in elderly. Use with caution in patients with severe aortic stenosis or heart failure with reduced ejection fraction. Abrupt discontinuation may cause rebound hypertension.
Adalat (nifedipine) is a dihydropyridine calcium channel blocker. Use immediate-release capsules only for hypertensive emergencies, not chronic treatment due to risk of reflex tachycardia and unpredictable hypotension. Extended-release formulations are preferred for stable angina and hypertension. Avoid grapefruit juice as it increases nifedipine levels via CYP3A4 inhibition. Monitor for peripheral edema, gingival hyperplasia, and constipation. Contraindicated in cardiogenic shock, severe aortic stenosis, and within 4 weeks of myocardial infarction.
Take exactly as prescribed, usually once daily.,Swallow tablet whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving until you know how you react.,Do not stop taking without consulting your doctor; sudden stop may worsen blood pressure.,Report swelling in ankles/feet, persistent cough, or irregular heartbeat.,Keep tablets in original container; protect from light and moisture.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit and grapefruit juice while taking this medication.,Report persistent swelling of ankles/feet, gum tenderness or bleeding, or severe dizziness.,Do not stop abruptly; taper under medical supervision to avoid rebound hypertension.,Take at the same time each day; if a dose is missed, skip it if near next dose.,May cause dizziness; avoid driving until you know how it affects you.,Increase fluid and fiber intake to prevent constipation.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCARDIA XL vs ADALAT, answered by our medical review team.
PROCARDIA XL is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.. ADALAT is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker; inhibits calcium ion influx across cardiac and vascular smooth muscle cells, reducing peripheral vascular resistance and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCARDIA XL and ADALAT depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCARDIA XL is: 30-90 mg orally once daily, extended-release tablet.. The standard adult dose of ADALAT is: 10-20 mg orally three times daily; extended-release: 30-60 mg orally once daily; maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCARDIA XL and ADALAT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCARDIA XL is classified as Category C. In animal studies, nifedipine caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies, phalangeal malformations) at doses 30-100 times the maximum recommended h. ADALAT is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; risk of preterm labor inhibiti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.